Vivien Wong, Ph.D.

Vivien Wong, Ph.D. is a pharmaceutical executive with over 20 years of experience in the development of drugs and diagnostics. Dr. Wong has held positions of increasing responsibility in Research and Development at Emisphere Technologies, Regeneron Pharmaceuticals, and most recently serving as Executive Vice President of Research and Development at Progenics Pharmaceuticals. At Regeneron, Dr. Wong pioneered translational pharmacology research that supported the development of Arcalyst®, Eylea®, Zaltrap®, Kevzara®, and Dupixent®. At Progenics, she led multifunctional teams to achieve FDA approval of Relistor® Subcutaneous Injection, Relistor® Tablets, AZEDRA®, and PYLARIFY®, including successes in obtaining Breakthrough Therapy, Fast Track, Priority Review, Orphan Drug, and Special Protocol Assessment designations for these products.

Dr. Wong currently serves as an independent advisor to pharmaceutical companies and venture capital firms. Her expertise includes identifying, evaluating, and developing product opportunities, as well as guiding small to mid-size pharmaceutical companies through drug development programs and regulatory processes.

Dr. Wong received her Ph.D. in Anatomy and Neurobiology from the University of Maryland School of Medicine and completed a postdoctoral fellowship in Neurology at the Albert Einstein College of Medicine. She is author on over 40 scientific publications in peer reviewed journals. She is a member of the Scientific Advisory Board of NeuroCuresNY, Inc., Board of Directors of Burke Neurological Institute, and an Advisor to the Westchester County Biosciences Task Force.